← Human Trials & Peer-Reviewed Studies
Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men.
Plain-language guide to PMID 15827107 (2005): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 15827107
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Johannsson G et al. (5 authors)
- DOI
- 10.1210/jc.2005-0553
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
The aim of this study was to investigate the effects of GH and testosterone, alone and in combination, on extracellular water (ECW) and the hormonal mechanisms involved.
Why It Was Studied
The mechanisms underlying the sodium-retaining effects of GH are poorly understood.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, men only.
How the Study Was Run
The design is described as randomized, open-label and crossover.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.
Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.
Two separate, open-label, randomized, two-period, crossover studies were performed; the first compared the effects of GH alone with those of GH and testosterone, and the second compared the effects of testosterone alone with those of GH and testosterone.
What Was Measured
PubMed files the paper under topics including Aldosterone, Atrial Natriuretic Factor, Body Water, Drug Synergism, Extracellular Fluid, Hormone Replacement Therapy and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.